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Echinocandins are considered first-line treatment for invasive Candida infections ([@B1]). However, treatment failures associated with resistant isolates harboring *fks* hot-spot mutations have been reported ([@B2], [@B3]). Nikkomycin Z is a chitin synthase inhibitor with potential therapeutic effects against Candida infections ([@B4]). Moreover, *in vitro* synergistic effects were reported when nikkomycin Z was combined with echinocandins against Candida isolates ([@B5], [@B6]). However, the effects of the combination *in vivo* are not yet available. In this study, we evaluated the *in vitro* effects of nikkomycin Z combined with an echinocandin (anidulafungin or micafungin) against two Candida albicans isolates (ATCC 90028 and blood culture isolate CA 46503) and their lab-derived echinocandin-resistant *fks* mutants. The *in vivo* effects of the antifungal combinations were studied in an immunosuppressed murine model.

Anidulafungin (Pfizer, Inc., USA), micafungin (Astellas Pharma, Inc., Japan), and nikkomycin Z (Sigma, USA) were used throughout the study. Spontaneous *fks* mutants of the two C. albicans parent strains were isolated by plating 10 μl (∼10^8^ cells) Sabouraud broth culture onto Sabouraud dextrose agar plates containing 8 μg/ml micafungin. Resistant isolates were reinoculated onto fresh plates containing 8 μg/ml micafungin to confirm the nonsusceptible phenotype. The isolates were characterized by *fks* hot-spot sequencing and antifungal susceptibility tests according to the CLSI broth microdilution method ([@B7], [@B8]). The nikkomycin Z MIC was the lowest drug concentration exhibiting 50% reduction in turbidity after 24 h of incubation. *In vitro* drug interactions were assessed by checkerboard assays with the fractional inhibitory concentration index (FICI) interpreted as follows: ≤0.5, synergistic; 0.5 to ≤4, indifferent; and \>4, antagonistic ([@B9]). Tests were done in duplicate. C. albicans *fks1* hot spot 1 was amplified with the forward primer BIO-1HS1F 5′-biotin-AATGGGCCGGTGCTCAACA-3′ and reverse (also sequencing) primer 1HS1-seq 5′-TTCACCATTACATCTCAT-3′. Corresponding primers for *fks1* hot spot 2 were BIO-1HS2F 5′-biotin-AAGATTGGTGCTGGTATGGG-3′ and 1HS2-seq 5′-ACCTCTTTCAATCAATTCTTGAACAAC-3′ ([@B10]). The *fks* hot spots were examined by pyrosequencing (PyroMark Q24; Qiagen, CA).

Murine models of systemic candidiasis were established in ICR mice (weighing ∼20 g) by intravenous inoculation of 100 μl (in a 1-ml syringe; Terumo, USA) of the four C. albicans strains (2 parents and 2 *fks* mutants; 5 × 10^6^ yeast cells) via tail vein ([@B11]). The mice were immunosuppressed by intraperitoneal injection of 100 mg/kg dexamethasone on days −3, 0, 7, and 14. Therapy began 1 day postinfection and continued for 12 days. A dose of 5 mg/kg of and echinocandin (anidulafungin or micafungin) was given subcutaneously once daily ([@B12], [@B13]). A dose of 10 mg/kg of nikkomycin Z was given subcutaneously twice daily ([@B14]). All mice were held for 17 days and monitored daily for mortalities. There were 10 mice per group. Kaplan-Meier survival plots were analyzed by a log-rank test (Prism, version 7.03; GraphPad Software, CA). *P* values were considered significant at the 0.05 level. All animal studies were approved by the Institutional Review Board.

Two spontaneous *fks* mutants, ATCC90028fksmtS645Y and CA46503fksmtS645P, were derived from C. albicans ATCC 90028 and CA 46503, respectively. Both mutants harbored a single substitution mutation in the *fks1* hot-spot region, and both were homozygous. The MIC results and FICIs are shown in [Table 1](#T1){ref-type="table"}. The *fks* mutants showed 32-fold elevations in MIC for anidulafungin and micafungin. Synergistic effects (nikkomycin Z and echinocandin) were observed in the parent strains and the *fks* mutants. Kaplan-Meier survival curves are shown in [Fig. 1](#F1){ref-type="fig"}. In the saline treatment control group, C. albicans ATCC 90028 was more virulent than CA 46503. The killing rates of the parent strains and their derived *fks* mutants were similar. Monotherapy with nikkomycin Z prolonged the survival of all infected mice (log-rank test, *P* \< 0.01), but the survival rates declined once the nikkomycin Z was discontinued. Treatment with either anidulafungin or micafungin improved the survival of mice infected with the parent strain but not in those infected with the *fks* mutants. Combination treatment with nikkomycin Z and either echinocandin significantly improved the survival rate of mice infected with the *fks* mutants compared with that of mice treated with nikkomycin Z or echinocandin monotherapy (log-rank test, *P* \< 0.02).

###### 

MIC and FICI values of C. albicans parent strains and their lab-derived *fks* mutants

  C. albicans strain   FKS hot-spot region   MIC (μg/ml) of[^*a*^](#T1F1){ref-type="table-fn"}:   Drug combination[^*b*^](#T1F2){ref-type="table-fn"}   MIC of combination (μg/ml)   FICI[^*c*^](#T1F3){ref-type="table-fn"}   Interpretation          
  -------------------- --------------------- ---------------------------------------------------- ----------------------------------------------------- ---------------------------- ----------------------------------------- ---------------- ------ ---------
  ATCC 90028           Wild type             0.03 (S)                                             0.03 (S)                                              4                            ANF + NZ                                  0.004 + 1        0.38   Synergy
  MCF + NZ             0.004 + 1             0.38                                                 Synergy                                                                                                                                              
  ATCC 90028mtS645Y    FKS1 S645Y            1 (R)                                                1 (R)                                                 4                            ANF + NZ                                  0.125 + 1        0.38   Synergy
  MCF + NZ             0.125 + 1             0.38                                                 Synergy                                                                                                                                              
  CA 46503             Wild type             0.03 (S)                                             0.03 (S)                                              4                            ANF + NZ                                  0.004 + 1        0.38   Synergy
  MCF + NZ             0.004 + 1             0.38                                                 Synergy                                                                                                                                              
  CA 46503mtS645P      FKS1 S645P            1 (R)                                                1 (R)                                                 4                            ANF + NZ                                  0.125 + 1        0.38   Synergy
  MCF + NZ             0.125 + 1             0.38                                                 Synergy                                                                                                                                              

S, sensitive; R, resistant.

ANF, anidulafungin; MCF, micafungin; NZ, nikkomycin Z.

FICI, fractional inhibitory concentration index.
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In this study, spontaneous C. albicans fks mutants were derived to assess the effects of combinations of nikkomycin Z and echinocandins. The mutations, *fks1* T1933C (FKS1 S645P) and *fks1* C1934A (FKS1 S645Y), and their associated elevations in echinocandin MIC were also observed previously ([@B15], [@B16]). The maximum plasma concentrations of anidulafungin, micafungin, and nikkomycin Z were reported to be, respectively, 49.5, 53, and 49.5 μg/ml in murine ([@B13], [@B17], [@B18]) and 8, 16, and 6.42 μg/ml in human adults ([@B19], [@B20]). Our *in vitro* synergistic effects were observed at achievable plasma concentrations in murine and humans, suggesting that the effects are potentially useful *in vivo*. Although the mechanism of the synergy is not fully understood, it was reported that chitin synthesis was upregulated as a result of cell wall salvage pathways when C. albicans isolates were exposed to caspofungin ([@B21]). The simultaneous inhibition of chitin synthase and β-1,3-glucan synthase by nikkomycin Z and an echinocandin probably renders the salvage pathway useless and impairs construction of the cell wall.

The *in vivo* response in this study correlated well with the resistance phenotype. Monotherapy with echinocandin did not produce significant survival in *fks* mutant-infected mice. Their survival was enhanced by nikkomycin Z treatment; however, similar to a previous report, survival declined when treatment was discontinued ([@B14]). Combination treatment with nikkomycin Z and echinocandin prevented such a decline and significantly improved survival of the *fks* mutant-infected mice.

In contrast to previous reports that used immunocompetent murine models, presence of the *fks* mutations in C. albicans isolates was not associated with decreased virulence in our immunosuppressed murine model ([@B15], [@B22]). The use of dexamethasone as an immunosuppressant may have affected the virulence results. To the best of our knowledge, this is the first report to demonstrate the *in vivo* therapeutic effects of combined nikkomycin Z and echinocandin in treating *fks* mutation-associated echinocandin-resistant C. albicans infections. One limitation of this study was that we evaluated only one dosing regimen (nikkomycin Z at 10 mg/kg twice daily). Future studies are needed to determine the dose-dependent effect of nikkomycin Z.
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